The FDA has approved the BLA for Ospomyv™ and Xbryk™, biosimilars to Prolia (denosumab) and Xgeva (denosumab), respectively.

The FDA has approved two new biosimilars of denosumab-dssb to treat osteoporosis, increase bone mass, prevent ...

The Tigers announced Friday that non-roster outfielder Akil Baddoo underwent surgery on Thursday to repair a fracture in his ...

Compared with placebo, a preoperative and intraoperative infusion of tranexamic acid was associated with significant ...

to treat adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity, and to treat hypercalcemia ...

On February 13, 2025, the FDA approved Samsung Bioepis Co., Ltd.’s denosumab biosimilars, OSPOMYV™ (denosumab-dssb; 60 mg pre-filled syringe) ...

Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. Treatment of hypercalcemia ...

Several important steps should be taken and/or considered after the identification of an oral cavity lesion: Perform a ...

Clear cell sarcoma is deemed highly aggressive due to its early tendency to metastasize, genetic mutations, and difficulty in ...

Samsung Bioepis Co., Ltd. today announced that the European Commission (EC) has granted marketing authorization for OBODENCEtm (60mg pre-filled syringe) and XBRYKtm (120mg vial), denosumab biosimilars ...

A fitness influencer was forced to have his have his lower jaw amputated after he was diagnosed with a rare form of oral ...